No-Risk Blood Test for Down Syndrome
Mother's Blood DNA Test IDs Down Syndrome With No Risk to Fetus
Oct. 6, 2008 -- An early-pregnancy blood test promises to tell women whether their fetus has Down syndrome without the need for risky, invasive procedures.
First- and second-trimester screening tests can detect pregnancies at high risk of Down syndrome. Many women opt to terminate such pregnancies.
But even if it never comes to having to make such a heart-rending decision, Down syndrome screening can be anguishing.
Noninvasive ultrasound and blood tests can tell women whether they need more invasive tests. These confirmatory tests mean inserting a needle into the womb to sample amniotic fluid (amniocentesis) or snipping off a small piece of the placenta for analysis (chorionic villus sampling or CVS).
The vast majority of the time, these tests go smoothly. But there's a real risk they can cause a miscarriage. Moreover, by the time all these tests confirm Down syndrome, the pregnancy is often 18 or 19 weeks along -- making the decision to terminate even more emotionally difficult.
No wonder the decision to undergo Down syndrome screening is fraught with anxiety. It certainly was an anxious time for Stanford University bioengineer Stephen Quake, PhD, and his family, when his wife underwent amniocentesis during her first pregnancy and CVS during her second.
"It was nerve-wracking for all of us, and I can only imagine how the fetus felt," Quake tells WebMD.
Safe Blood Test for Down Syndrome
Quake started looking for a better way to screen. He knew that a small amount of fetal DNA enters a pregnant woman's bloodstream. Researchers already were trying to separate that DNA from the mother's own DNA, but were having little luck.
That's when Quake had a brainstorm. Down syndrome is a genetic defect -- an extra copy of chromosome 21. Quake realized it isn't necessary to separate fetal DNA from maternal DNA. All he had to do was count the DNA that belonged to chromosome 21. Too much of this DNA signaled a fetus with an extra chromosome.
"We sequence millions of molecules from each blood sample and map the DNA back to the chromosome. And then we look to see if any chromosomes are over-represented," Quake says.